Breaking News: Relief Therapeutics Gears Up for the Spotlight at the Prestigious H.C. Wainwright 25th Annual Global Investment Conference!

GENEVA, SWITZERLAND / ACCESSWIRE / September 1, 2023- Get ready for a dose of innovation and vision as Relief Therapeutics Holding SA (SIX: RLF) (OTCQB: RLFTF) (OTCQB: RLFTY), a trailblazing biopharmaceutical powerhouse, gears up to make waves at the prestigious H.C. Wainwright 25th Annual Global Investment Conference. Brace yourselves, because we’re about to embark on a journey of medical marvels.

Our guide on this thrilling adventure? None other than our visionary Chief Executive Officer, Jack Weinstein. He’s set to present a captivating company overview that promises to redefine the landscape of specialty, unmet, and rare disease treatments.

Circle your calendars for Wednesday, Sept. 13, 2023, at 12:30 p.m. EDT, and head to the Lotte New York Palace Hotel, 455 Madison Avenue at 50th Street, New York, NY 10022. That’s where the magic happens.

But here’s the cherry on top: We’re not just here to talk; we’re here to connect. Our management team is all set to host one-on-one meetings during the event. If you’re an institutional investor registered for the conference, don’t miss out on the opportunity to dive into the future of healthcare with us.

This isn’t just an event; it’s a rendezvous with innovation. Join us as we unveil the future of medical possibilities!


At Relief Therapeutics, we’re not just another biopharmaceutical company; we’re the architects of hope for those battling select specialty and rare diseases. Our mission isn’t just a statement; it’s a relentless pursuit of better treatments, improved safety, and enhanced convenience – all aimed at transforming the lives of patients worldwide.

Our arsenal? A powerful portfolio that combines proven, revenue-generating products with groundbreaking, globally patented technologies like Physiomimic™ and TEHCLO™. But that’s just the beginning. We’re not afraid to venture into uncharted territory, and our clinical development pipeline is brimming with promise, covering rare metabolic, rare dermatology, and rare respiratory diseases.

But we don’t stop there. We believe in legacy, and we’re breathing new life into older products by partnering with distribution experts. Our impact spans continents, with headquarters in Geneva, and strategic outposts in Balerna, Switzerland, Offenbach am Main, Germany, and Monza, Italy.

We’re not just a symbol on the stock exchange; we’re a symbol of relief for those who need it most. Join us on this journey, led by a global team of seasoned biopharma leaders, each armed with a wealth of research, development, and rare disease expertise. Relief Therapeutics isn’t just a name; it’s a promise – a promise to bring therapeutic relief to the brave souls facing rare diseases worldwide.

Leave a Comment